Detalhe da pesquisa
1.
Modelling atopic dermatitis in healthy human skin for the characterization of topical compounds.
Exp Dermatol
; 33(5): e15099, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38794814
2.
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug Disposition.
Drug Metab Dispos
; 50(12): 1472-1482, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195338
3.
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Exp Dermatol
; 31(10): 1522-1532, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638561
4.
ß-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
J Allergy Clin Immunol
; 139(3): 923-932.e8, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502297
5.
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.
Clin Transl Sci
; 17(2): e13724, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407540
6.
Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.
J Dermatolog Treat
; 34(1): 2138691, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36305633
7.
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis.
J Invest Dermatol
; 143(10): 1896-1905.e8, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004878
8.
Disease Association of AntiâCarboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.
J Invest Dermatol
; 143(2): 273-283.e12, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116506
9.
Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.
Exp Dermatol
; 25(2): 157-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26439798
10.
Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
Expert Opin Drug Discov
; 16(12): 1483-1495, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34191664
11.
Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4.
J Invest Dermatol
; 140(12): 2421-2432.e10, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387270
12.
A new ecamsule-containing SPF 40 sunscreen cream for the prevention of polymorphous light eruption: a double-blind, randomized, controlled study in maximized outdoor conditions.
Cutis
; 83(2): 95-103, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19326695
13.
Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study.
J Dermatol Sci
; 49(3): 241-8, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18063345
14.
Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy.
Eur J Dermatol
; 18(5): 524-6, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18693154
15.
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
J Clin Pharmacol
; 57(7): 876-885, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273356
16.
Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations.
Cutis
; 72(1): 76-81, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12889719
17.
Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients.
J Dermatolog Treat
; 22(4): 197-205, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20666678